A randomized, double-blind, multicenter, phase II, three-arm, placebo-control study of apatinib as third-line treatment in patients with metastatic gastric carcinoma.
J. Li
No relevant relationships to disclose
S. Qin
No relevant relationships to disclose
J. Xu
No relevant relationships to disclose
W. j. Guo
No relevant relationships to disclose
J. p. Xiong
No relevant relationships to disclose
Y. Bai
No relevant relationships to disclose
G. Sun
No relevant relationships to disclose
Y. Yang
No relevant relationships to disclose
L. Wang
No relevant relationships to disclose
N. Xu
No relevant relationships to disclose
Y. Cheng
No relevant relationships to disclose
W. Zhe-Hai
No relevant relationships to disclose
L. Zheng
No relevant relationships to disclose
M. Tao
No relevant relationships to disclose